Cantor Fitzgerald Comments on Alumis FY2026 Earnings

Alumis Inc. (NASDAQ:ALMS) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Alumis in a report released on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will post earnings of ($2.60) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share.

ALMS has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Alumis in a research note on Wednesday, April 30th. Oppenheimer dropped their target price on Alumis from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Thursday, May 15th. Finally, Guggenheim assumed coverage on shares of Alumis in a report on Tuesday. They set a “buy” rating and a $18.00 price target for the company. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Alumis has an average rating of “Buy” and an average target price of $22.86.

Alumis Stock Up 0.7%

Alumis stock opened at $3.46 on Tuesday. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53. The firm’s fifty day moving average price is $5.16 and its 200-day moving average price is $6.19.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($1.47) by ($0.35).

Insider Buying and Selling at Alumis

In other Alumis news, major shareholder Foresite Labs, Llc acquired 20,000 shares of the stock in a transaction dated Tuesday, May 6th. The shares were purchased at an average price of $4.34 per share, for a total transaction of $86,800.00. Following the purchase, the insider now directly owns 4,247,670 shares of the company’s stock, valued at approximately $18,434,887.80. This trade represents a 0.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Martin Babler purchased 15,650 shares of Alumis stock in a transaction on Tuesday, April 1st. The stock was bought at an average price of $6.44 per share, with a total value of $100,786.00. Following the transaction, the chief executive officer now owns 106,454 shares of the company’s stock, valued at approximately $685,563.76. This represents a 17.23% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 397,044 shares of company stock valued at $1,891,895.

Hedge Funds Weigh In On Alumis

A number of hedge funds have recently modified their holdings of ALMS. Towerview LLC boosted its holdings in Alumis by 9.2% in the 4th quarter. Towerview LLC now owns 415,000 shares of the company’s stock worth $3,262,000 after buying an additional 35,000 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Alumis by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company’s stock valued at $891,000 after acquiring an additional 4,808 shares during the last quarter. Norges Bank purchased a new position in shares of Alumis in the fourth quarter valued at $1,606,000. Geode Capital Management LLC increased its position in Alumis by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 315,571 shares of the company’s stock worth $2,481,000 after purchasing an additional 9,891 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after purchasing an additional 3,823 shares in the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.